SynthesisBMC infectious diseases2026
Visceral leishmaniasis in leukemia patients, a great neglected disease in endemic countries: report of a retrospective study and systematic literature review.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVisceral leishmaniasis (VL) is an emerging infectious disease caused by the genus Leishmania and shares clinical features with some types of leukemia.
methodsIn a retrospective study (2020-2022), bone marrow aspirates (BMAs) from 52 children with leukemia in Ardabil Province, northwestern Iran, were examined for the presence of VL via microscopy and specific polymerase chain reaction (PCR) methods. Additionally, the results of a systematic review of the literature on VL in these patients were reported.
resultsIn our retrospective study, microscopic investigations of BMA slides from 52 children with leukemia did not reveal Leishmania amastigotes. However, PCR detected amastigotes in three BMAs (5.8%). Simultaneously, a systematic review was designed, and 53 cases of VL with leukemia were retrieved. Half of these cases were from Brazil. Most cases were observed in children and adolescents (77.3%), with a higher prevalence in men (67.8%). The most common clinical and laboratory findings were: splenomegaly (96%), fever (90.5%), and anemia (92%). Acute lymphoblastic leukemia (ALL) was the most prevalent type of leukemia (66%). The systematic review on diagnostic accuracy showed that the serological method (sensitivity: 85%) proved to be more reliable than the microscopic method (sensitivity: 55%), while the PCR method detected all cases of leishmaniasis. Patients treated with anti-Leishmania drugs improved, except for one patient whose VL was reactivated one year later.
conclusionVL should be added to the list of possible differential diagnoses of leukemia patients, particularly in endemic areas, and physicians' awareness of this condition prevents unnecessary invasive diagnostic procedures. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.